News

WASHINGTON–(BUSINESS WIRE)–Parker Health an innovative biotech company for electronic health records, hospital developer & management, and subscription-based health services, today announced that it has secured $25 million in Series A funding led by Bias Capital a multisector and multi-stage angel syndicate joined in this round by L’PAJ Ventures, CGT Capital Group, and other angel investors and family offices. This funding empowers Parker Health to further its position as the industry’s most compliant and competitive solution helping expand our medical technology and services and to employ global teams. Parker Health has raised $26.3 million to date.

Applicants are encouraged to review the 2023 SBIR and STTR Omnibus Notices of Funding Opportunity (NOFOs).These NOFOs encourage small businesses to submit grant applications to NIH, CDC, and FDA for innovative ideas across the HHS mission space. The new NOFOs are listed below:

Baltimore-based Digital Health Startup is Working to End Medication Errors and Streamline Workflows in Long-Term Care Settings

Baltimore, Md. (July 11, 2023) – Impruvon Health (“Impruvon”), a Baltimore-based digital health startup, announced today that it closed a financing round to support surging demand from healthcare organizations for its enterprise medication management platform. The round is led by The Propel Baltimore Fund from TCP Venture Capital, with participation from the University System of Maryland (USM) Momentum Fund (Momentum Fund) and New Dominion Angels.

The Maryland Tech Council, the largest technology and life sciences trade association in the state, today welcomed a new chair and slate of technology and life sciences leaders to its board of directors. The new members join the board as MTC enjoys rapid growth in its membership, educational programs, and workforce development initiatives.

“I am thrilled to welcome these new members, who represent some of the most respected companies in Maryland’s innovation ecosystem,” said Kelly Schulz, CEO of the Maryland Tech Council. “Our ability to educate, connect, and advocate for members depends on diverse perspectives from creative and forward-thinking board members. I look forward to working with our board as we seek to make our state the destination of choice for innovators.”

New Device Provides an Effective, Hands-Free Solution to Stop Nosebleeds in Children and Adults

Adult and Pediatric NasaClip Sizes Provide Easy-To-Use Options for Chronic Nosebleed Sufferers, Healthcare Professionals, Parents, and Schools; First Available, U.S. Food and Drug Administration Registered Device with Age-Appropriate Sizing for Patients Aged 2 and Older

BALTIMORE, MD. (PRWEB) JULY 11, 2023

NasaClip, Inc., a Baltimore-based medical device company focused on improving the lives of patients with nosebleeds and the healthcare professionals who treat them today introduced the NasaClip, an easy-to-use device that provides constant, comfortable hands-free compression combined with intranasal sponges to stop nosebleeds quickly. NasaClip comes in an adult size for ages 14+, and pediatric size for children ages 2 to 13. It is the first nosebleed rescue device that provides adjustable nasal compression for children and adults and is registered with the U.S. Food and Drug Administration (FDA).

Responding faster and more effectively to future public health challenges and emergencies will require the development of a specific, rapid acquisition vehicle. To achieve this, BARDA is launching the Rapid Response Partnership Vehicle (RRPV), the next generation of acquisition partnering to support U.S. health security.

In alignment with objectives outlined in the 2022-2026 Strategic Plan, BARDA seeks to leverage its Other Transaction Authority (OTA) to develop the RRPV. The RRPV will complement BARDA’s existing acquisition vehicles such as the Broad Agency Announcement (BAA) and the Easy Broad Agency Announcement (EZ-BAA) and will expand the mechanisms through which BARDA can rapidly partner with product developers prior to and during an emergency response. With the RRPV in place, BARDA will be able to leverage OTA agreements to meet the dynamic needs of the BARDA mission through a streamlined, expedited process.

The long-awaited grand opening of the Sfax University Simulation Center has finally arrived, marking a new era of innovative learning and development in Sfax, Tunisia. The cutting-edge center promises to provide a hub for experiential learning, creating a springboard for high-potential projects to flourish. In the run-up to the opening, the team at the Simulation Center, supported by Johns Hopkins University,  held a series of fruitful meetings with local stakeholders. During these sessions updates were shared, and attendees were encouraged to submit their high potential projects for consideration, initiating direct engagement with the local community.

Now in its 8th year, the BioHealth Capital Region Crab Trap continues to grow, attracting applicants from around the region, country, and internationally. The competition highlights entrepreneurs with commercially relevant diagnostics, medical devices, therapeutics, and other transformative health solutions.

This year’s Crab Trap winner will be eligible for a package of prizes worth more than $50,000. Prizes for the qualifying Crab Trap winner include:

• A $10,000 cash prize from Greenberg Traurig
• A $25,000 cash prize from Montgomery County (for a firm headquartered in Montgomery County)
• A one-year residency at JLABS @ Washington, D.C. (for a firm of their choice)
• $10,000 in Preclinical CRO services from Noble Life Sciences.

MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support Vittoria’s Senza5™ technology to enhance efficacy and improve clinical utility of T-cell therapies.

ROCKVILLE, Md. and PHILADELPHIA, July 10, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.

FREDERICK, MARYLAND, July10, 2021: BioFactura, Inc. today announced that CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has entered into an exclusive license to commercialize BFI-751, BioFactura’s proposed biosimilar to Stelara (Ustekinumab). Ustekinumab is a recombinant monoclonal antibody that works by blocking both interleukins IL-12 and IL-23 and is used for treating Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. The global drug sales of Ustekinumab stood at close to 10 billion in 2022 presenting a significant opportunity with a good number of indications and a wider use.